A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer

Atezolizumab will be given to participants intravenously at a dosage of 1680 mg on day 1 of each 28-day cycle.

Bevacizumab will be given to participants intravenously at a dosage of 10mg per participant kilogram every 2 weeks of the 28-day cycle.

Ipatasertib will be given as an orally at a dosage of 400 mg once daily for 21 days of each 28-day cycle.

Talazoparib will be given in an orally at a dosage of 1 mg once daily for each day of the 28-day cycle.

Trastuzumab emtansine be given to participants intravenously at a dosage of 3.6 mg per participant kilogram, on day 1 of each 21-day cycle.

Tiragolumab will be given to participants intravenously at a dosage of 840 mg on day 1 of each 28-day cycle.

Atezolizumab will be given to participants intravenously at a dosage of 1200 mg on day 1 of each 21-day cycle.

Inavolisib will be given in an orally at a dosage of 9 mg once daily for each day of the 28-day cycle.

Letrozole will be given orally at a dosage of 2.5 mg once daily for each day of the 28-day cycle.

Giredestrant will be given orally at a dosage of 30 mg once daily for each day of the 28-day cycle.

Giredestrant will be given orally at a dosage of 150 mg twice daily for each day of the 28-day cycle.